Company intelligence / Profile preview
Mirscience Therapeutics
São Paulo, São Paulo, Brazilmirsciencetx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mirscience Therapeutics has developed miRNA-based oligonucleotide molecules using its proprietary platform, with preclinical data showing anti-muscle atrophy effects, hypertrophy, and functional improvement in skeletal muscle. The company’s lead candidate targets MURF‑1 and Atrogin‑1, key regulators of muscle degradation. No human trials have started yet; next steps include studies in non-human primates before IND-enabling work begins.
- Therapeutic areas
- RheumatologyMetabolic DisordersOncology
- Modalities
- microRNA-based oligonucleotides (miRNA therapies)RNA therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Green Rock VC (investor/partner)Eretz.Bio (investor/partner/incubator)
Beyond the preview
Go deeper on Mirscience Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mirscience Therapeutics.